



# CERTIFICATE OF ANALYSIS




## Product Details

Product name:	Anti-EGFR & HER3 Reference Antibody (Duligotuzumab)	Lot.No.:	P248572C2
Target:	ERBB1 / EGFR / HER1, ERBB3 / HER3	Catalog:	CHBA007
Target Accession:	P00533 & P21860	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	144.78 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0   Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


# Data

## MASS




The detected molecular weight of Anti-EGFR & HER3 Reference Antibody (Duligotuzumab) is 144.47 kDa.

## Purity: SDS-PAGE




Anti-EGFR & HER3 Reference Antibody (Duligotuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

## Purity: SEC-HPLC



The purity of Anti-EGFR & HER3 Reference Antibody (Duligotuzumab (USAN)) is 100%, determined by SEC-HPLC.


## ELISA



Duligotuzumab bound to EGFR protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Duligotuzumab bound to Human EGFR-his, and the EC50 was 0.002 nM.


The products are for research use only. Not for use in diagnostic procedures.

## ELISA




Duligotuzumab bound to HER3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Duligotuzumab bound to Human-HER3-his, and the EC50 was 0.002 nM.

## Bioactivity: FACS



Duligotuzumab bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Duligotuzumab bound to EGFR-CHO-K cells, and the EC50 was 0.937 nM.

## Bioactivity: FACS



Duligotuzumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Duligotuzumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and the EC50 was 0.645 nM.

The products are for research use only. Not for use in diagnostic procedures.